Development and Evaluation of a Polyherbal Tablet for Polycystic Ovarian Syndrome (PCOS)


  • Parul University, Parul Institute of Pharmacy and Research, Vadodara, Gujarat, 391110, India
  • Parul University, Parul Institute of Pharmacy, Vadodara, Gujarat, 391110, India


The main objective of the present study was to develop and evaluate polyherbal tablet for the treatment of Polycystic Ovarian Syndrome (PCOS). For the formulation of tablet, the herbs were selected based on the concepts of pathophysiology and Ayurvedic perspective of the disease. The extracts of T. foenum graceum, C. longa, B. aristata, S. asoka, B. variegata and Guggul purified in cow’s urine was used for the preparation of polyherbal tablet. The physicochemical, phytochemical evaluation and quantification of markers by HPTLC of crude drugs and extracts were performed. The guggul was used as binder in different proportion for the preparation of tablet. Pre-formulation study of the powder blend and post compression evaluation of tablet was done by various parameters like weight variation, friability, hardness, thickness, diameter, disintegration time, in-vitro dissolution and accelerated stability study. The physicochemical evaluations of crude drugs yielded results which were in accordance with the monograph’s standard values. The phytochemical analysis of the extracts revealed the presence of variety of phytoconstituents. From the results of HPTLC quantification the amount of curcumin (7.14%) in C. longa, diosgenin (40.6%) in T. foenum graceum ,T. foenum graceum, berberine hydrochloride (4.83%) in B. aristata, catechin (3.48%) in S. asoka, lupeol (0.11%) in B. variegata and Z-guggulsterone (0.140%) and E-guggulsterone (0.146%) in purified guggul was found. The micrometrics of the powder blend of all the formulations showed good flow properties. Formulation F3 showed better results compared to other formulations in post compression evaluation. Accelerated stability study showed that the formulation F3 was stable during the course of study.


Micromeritics, Polyherbal Formulation, Polycystic Ovarian Syndrome, Physicochemical Evaluation

Subject Discipline

Pharmacy, Pharmacognosy

Full Text:


Azeemuddin M, Anturlikar SD, Onkaramurthy M, Baig MR, Ashok BK, Rao RP, et al., Effect of “dXB- 2030,” a polyherbal formulation, on Experimental polycystic ovary syndrome associated with hyperandrogenism. Adv Pharmacol Sci. 2019; 2019. PMid:30863446. PMCid:PMC6378078

Patel MG, Prjapathi DP. Concept of polycystic ovarian syndrome: Perspectives of Ayurveda and Modern Science. Int J Pharmacogn Phytochem Res. 2017; 9(10):1363-72.

Arentz S, Abbott J, Smith C. Herbal medicine for the management of polycystic ovary syndrome (PCOS). BMC Complim Altern Med. 2014; 14(2015):511- 30. PMid:25524718. PMCid:PMC4528347

Moorthy R, Prabhu KM, Murthy PS. Antihyperglycemic compound (gII) from fenugreek (Trigonella foenum-graecum linn.) seeds, its purification and effect in diabetes mellitus. Indian J Exp Biol. 2010; 48(11):1111-8.

Renuka C, Ramesh N, Saravanan K. Evaluation of the antidiabetic effect of Trigonella foenum-graecum seed powder on alloxan-induced diabetic albino rats. Int J Pharm Tech Res. 2009; 1(4):1580-4.

Mohammadi A, Gholamhosseinian A, Fallah H. Trigonella foenum-graecum water extract improves insulin sensitivity and stimulates PPAR and ? gene expression in high fructose-fed insulin-resistant rats. Adv Biomed Res. 2016; 5(1):54. PMid:27110551 PMCid:PMC4817393

Swar G, Shailajan S, Menon S. Activity based evaluation of a traditional Ayurvedic medicinal plant: Saraca asoka (Roxb.) de Wilde flowers as estrogenic agents using ovariectomized rat model. J Ethnopharmacol. 2017; 195:324-33. PMid:27884717

Cibin TR, Devi DG, Abraham A. Chemoprevention of two-stage skin cancer in vivo by Saraca asoca. Integr Cancer Ther. 2012; 11(3):279-86. https://doi. org/10.1177/1534735411413264. PMid:21771821

Jadhav AN, Bhutani KK. Ayurveda and gynecological disorders. J Ethnopharmacol. 2005; 97(1):151- 9. PMid:15652289

Shahid AP, Salini S, Sasidharan N, Padikkala J, Raghavamenon AC, Babu TD. Effect of Saraca asoka (Asoka) on estradiol-induced keratinizing metaplasia in rat uterus. J Basic Clin Physiol Pharmacol. 2015; 26(5):509-15. jbcpp-2014-0124. PMid:25915082

Dhiman K. Ayurvedic intervention in the management of uterine fibroids: A Case series. AYU (An Int Q J Res Ayurveda). 2014; 35(3):303. PMid:26664240. PMCid:PMC4649577

Rajkapoor B, Jayakar B, Murugesh N. Antitumour activity of Bauhinia variegata on Dalton’s ascitic lymphoma. J Ethnopharmacol. 2003; 89(1):107-9.

S R, H. P. Alternative therapies in polycystic ovarian syndrome. Insulin. 2010; 1(2):3.

Upwar N, Patel R, Waseem N, Mahobia NK. Hypoglycemic effect of methanolic extract of Berberis aristata DC stem on normal and streptozotocin induced diabetic rats. Int J Pharm Pharm Sci. 2011; 3(1):222-4.

Orio F, Muscogiuri G, Palomba S, Savastano S, Volpe A, Orio M, et al., Berberine improves reproductive features in obese Caucasian women with polycystic ovary syndrome independently of changes of insulin sensitivity. ESPEN J. 2013; 8(5):e200-4.

Razzaq FA, Khan RA, Feroz Z, Afroz S. Effect of Berberis aristata on lipid profile and coagulation parameters. African J Pharm Pharmacol. 2011; 5(7):943-7.

Sidhu GS, Mani H, Gaddipati JP, Singh AK, Seth P, Banaudha KK, et al., Curcumin enhances wound healing in streptozotocin induced diabetic rats and genetically diabetic mice. Wound Repair Regen. 1999; 7(5):362-74. 475X.1999.00362.x. PMid:10564565

Reddy PS, Begum N, Mutha S, Bakshi V. Beneficial effect of Curcumin in Letrozole induced polycystic ovary syndrome. Asian Pacific J Reprod. 2016; 5(2):116- 22.

Edition F. the Pharmacopoeia of the Pharmacopoeia of. 2016;

on Traditional Medicine WHOP. Guidelines for the assessment of herbal medicines. World Health Organization; 1991.

Organization WH. WHO guidelines on good manufacturing practices (GMP) for herbal medicines; 2007. p. 72.

Khandelwal K. Practical pharmacognosy. Pragati Books Pvt. Ltd.; 2008.

Gupta AK, Tondon N, Sharma M. Quality standards of Indian medicinal plant medicinal plants unit: Published by Indian Council of Medical Research. New Delhi. 2008;3:99-105.

Chaube A, Dixit SK, Sharma P V. On improving the disintegration of ayurvedic pills containing guggulu. Anc Sci Life. 1995; 14(3):161-7.

Savarikar SS, Barbhind MM, Kulkarni AP. Pharmaceutical and analytical evaluation of Triphala guggul kalpa tablets J Ayurveda Integr Med. 201; 2(1):21-25.

Mohini U, Pallavi R, Shashikant D, Nilesh K. Assessment of guggul gum as a binding agent in tablet formulations. Res J Pharm Technol. 2013; 6(3): 238-9.

M Hedaoo M, Patil Bhole TPB. Narrative review of guggulu formulations of ayurveda reflecting their percentage of guggulu, pharmaceutics and pharmacology. IP Int J Compr Adv Pharmacol. 2021; 5(4):151-7. 2020.031

Khar RK. Lachman/liebermans: the theory and practice of industrial pharmacy. Cbs Publishers & Distribu; 2013.

Aulton ME, Taylor KMG. Aulton’s pharmaceutics. Des Manuf Med. 2007; 3:176-8.

Pharmacopoeia I. Government of India. Minist Heal Fam Welf. 2007; 2:1020-1.

Kushwaha SK, Kori ML. Development and evaluation of polyherbal syrup from some hepatoprotective medicinal plants. 2014; 1(1):5-11.

Balekundri A, Shahapuri A, Patil M. Poly-herbal tablet formulation by design expert tool and in vitro antilipase activity. Futur J Pharm Sci. 2020; 6(1). https://

Maurya H, Kumar T. Formulation, standardization, and evaluation of polyherbal dispersible tablet. Int J Appl Pharm. 2019; 11(1):158-67. https://doi. org/10.22159/ijap.2019v11i1.30113

Mamatha D. Formulation and evaluation of poly herbal anti-diabetic tablet dosage form. Int J Ayurvedic Herb Med. 2018; 6:2956-62. ijahm/v7i6.06

Puri D, Bhandari A, Sharma K, Sharma P. Formulation and evaluation of antihelminthic polyherbal tablets. Int J Green Pharm. 2011;5(1):39-42.

Guideline ICHHT. Stability testing of new drug substances and products. Q1A (R2), Curr step. 2003; 4:1-24.


  • There are currently no refbacks.